Johnson & Johnson Q1 Sales Rise 6.4% to $24.1B, Raises Guidance
Johnson & Johnson reported Q1 operational sales of $24.1 billion, up 6.4%, with adjusted diluted EPS of $2.70 despite a 2.5% year-over-year decline. The company raised 2026 operational sales growth guidance to 5.9%–6.9% and increased its annual dividend by 3.1% to $5.36 per share.
1. Q1 Financial Performance
Johnson & Johnson delivered $24.1 billion in worldwide sales, an operational increase of 6.4%, with net earnings of $5.2 billion. Adjusted net earnings totaled $6.6 billion, yielding adjusted diluted EPS of $2.70, down 2.5% year-over-year, while Innovative Medicine sales rose 7.4% to $15.4 billion and MedTech grew 4.6% to $8.6 billion.
2. 2026 Outlook and Dividend Increase
The company raised its 2026 operational sales growth guidance to a range of 5.9%–6.9% and lifted adjusted operational EPS guidance to $11.30–$11.50, implying 5.7% midpoint growth. The board approved a 3.1% dividend increase, raising the annual rate to $5.36 per share.
3. Pipeline and Product Developments
Johnson & Johnson maintains 28 platforms or products each generating at least $1 billion in annual revenue, targeting $100 billion in total revenue by year-end 2026. The new oral peptide ICOTYDE has seen strong early physician uptake and is in active payer discussions for broad coverage, while STELARA sales declined 61.7% due to biosimilar competition.